In 2020, the global Peptide Synthesis market created revenue of 879.9 million dollars and is expected to reach 1419.9 million dollars by 2026. During this forecast period, the market will grow at a compound annual growth rate of 13.0%.
Peptide molecules have received great attention in the healthcare and nutrition industries, and technological progress has made peptide production/synthesis a reality. This trend is very obvious in the fields of enzyme peptide synthesis and chemical peptide synthesis.
The highest revenue from reagent consumables.
Table of Contents
Chemical Synthesis of Peptide
Chemical synthesis is considered to be a conventional and widely used technology for peptide production, but the lack of specificity and increased risk of environmental burden will hinder the development of chemical Peptide synthesis. This has promoted the application of enzymatic technology in peptide synthesis, but the disadvantages of this technology are low production efficiency, expensive biocatalysts and lack of validation schemes, which pose challenges to peptide production.
In order to develop appropriate Peptide synthesis technologies, manufacturers combine enzymatic and chemical synthesis methods to synergistically utilize the advantages of the two technologies.
According to product types, the global Peptide synthesis market can be divided into three categories, namely equipment, reagents and consumables. Peptide synthesis equipment can be analyzed through four sub parts, including protein synthesizer, lyophilizer, chromatography equipment, etc
Among other Peptide synthesis products, reagents and consumables generate the highest income because they are routinely used in Peptide synthesis schemes. In addition, the development related to peptide coupling reagents in recent years is expected to drive market growth in the coming years.
Liquid-phase Peptide Synthesis Dominates
In terms of peptides, this market is divided into 3 parts, namely solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS) , and mixed technology. Throughout the forecast period, LPPS will dominate the global market, while SPPS will show its fastest growth rate from 2019 to 2026.
The implementation of automation in both liquid and solid-phase Peptide synthesis has lessened the expenditure connected to Peptide synthesis and is likely to grow the utilization of Peptide synthesis across the world, adding to the worldwide income attained in the anticipated timeframe.
Studies conducted previously have concluded that solid-phase peptide synthesis is a reliable and cost-efficient technique for manufacturing products that require good manufacturing practices and for developing active pharmaceutical ingredients. It is able to effectively formulate chains that contain more than 10 amino acids. However, the process of purifying the proteins from the peptides can bump up these expenses.
Although liquid-phase Peptide synthesis is most commonly used to develop shorter peptide sequences and larger volumes, hybrid techniques are used to synthesize large quantities of long peptide sequences.
Strong Growth in the Treatment Industry
From the perspective of the application, the Peptide synthesis market is subdivided into treatment, diagnosis, and research. The treatment niche market includes treatments for diseases such as cancer, metabolism, cardiovascular, respiratory, gastrointestinal, infectious diseases, pain, dermatology, central nervous system, and kidney.
In 2022, the treatment market segment will dominate the application market of Peptide synthesis and is expected to continue this trend in the forecast period. From 2013 to 2026, the diagnostic segment market is expected to grow at its fastest pace.
Synthetic peptides are widely used in cancer and have become a major contributor to the revenue of the treatment segment. In addition, in the forecast period, metabolic diseases are expected to grow at the fastest rate, which is due to the strong product R&D line and a large number of candidate peptide drugs for the treatment of type 2 diabetes.
From the perspective of end use, the Peptide synthesis market is divided into three parts, including pharmaceutical and biotechnology companies, contract development and production organizations (CMOs)/contract research organizations (CROs), and academic and research institutions. The strong growth of the peptide therapy industry is the main driving factor for pharmaceutical and biotechnology companies to dominate, with CRO and CMO having the highest growth rates between 2019 and 2026.
The North American market contributes the most to Peptide Research.
The demand for Peptide synthesis technology in North America, Asia Pacific, Latin America, the Middle East, and Africa, and other areas has seen an uptick, with North America being the most prominent contributor to the global market. This is due to the presence of many local market players, heightened awareness of Peptide synthesis technology, and increased attention toward the commercialization of peptide drugs.
Over the projected timeframe, the Asia Pacific region is anticipated to experience the highest growth rate due to the heightened expenditure of business participants in the area, growing awareness of new polypeptide medicinal drugs, the expansion in health care spending from both government and patients, the collaboration between multinational business entities and local market players to distribute products, and the increase in chronic illness prevalence among low- and middle-income countries.
For many years, this market has also had many mergers and acquisitions cases. In January 2018, Imcyse announced a research collaboration with Pfizer to develop a specifically modified peptide Mimotope. This peptide is synthesized and used to treat Rheumatoid arthritis. Imcyse produces active targeted immune drugs for the treatment of chronic diseases.
Major Peptide Synthesis Manufacturers Worldwide
Some major players in the peptide synthesis market include Genscript Biotechnology, Merck, Bachem Holdings, Biotage, CEM Corporation, Omizzur Ltd, Thermo Fisher, Creative Diagnostics, Polypeptide Group, Syngene, PuroSynth, Lonza MP Biomedicals, and Novo Nordisk.
